These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38950998)

  • 1. Trends in antidiabetes medication use among hospitalised patients with type 2 diabetes: a retrospective single-centre cohort study.
    Meier N; Laager R; Gregoriano C; Schütz P; Mueller B; Struja T; Kutz A
    BMJ Open; 2024 Jul; 14(6):e084526. PubMed ID: 38950998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of early use of sodium-glucose transport protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on the legacy effect of hyperglycemia.
    Deng S; Zhao H; Chai S; Sun Y; Shen P; Lin H; Zhan S
    Front Endocrinol (Lausanne); 2024; 15():1369908. PubMed ID: 38803473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes.
    O'Brien MJ; Karam SL; Wallia A; Kang RH; Cooper AJ; Lancki N; Moran MR; Liss DT; Prospect TA; Ackermann RT
    JAMA Netw Open; 2018 Dec; 1(8):e186125. PubMed ID: 30646315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.
    Komuro I; Kadowaki T; Bodegård J; Thuresson M; Okami S; Yajima T
    Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():19-27. PubMed ID: 33835641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.
    Fu EL; Mastrorilli J; Bykov K; Wexler DJ; Cervone A; Lin KJ; Patorno E; Paik JM
    Kidney Int; 2024 Mar; 105(3):618-628. PubMed ID: 38101515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom.
    Brunetti VC; St-Jean A; Dell'Aniello S; Fisher A; Yu OHY; Bugden SC; Daigle JM; Hu N; Alessi-Severini S; Shah BR; Ronksley PE; Lix LM; Ernst P; Filion KB;
    BMC Endocr Disord; 2022 Sep; 22(1):241. PubMed ID: 36175881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status.
    Bea S; Jeong HE; Filion KB; Yu OH; Cho YM; Lee BH; Chang Y; Byrne CD; Shin JY
    JAMA Netw Open; 2023 Dec; 6(12):e2349856. PubMed ID: 38153732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA.
    Shin H; Schneeweiss S; Glynn RJ; Patorno E
    Diabetes Care; 2021 Aug; 44(8):1774-1782. PubMed ID: 34385345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between sodium glucose cotransporter-2 inhibitors vs dipeptidyl peptidase-4 inhibitors and renal outcomes in people discharged from hospital with type 2 diabetes: A population-based cohort study.
    Ziser KED; Wood S; Tan GSQ; Morton JI; Shaw JE; Bell JS; Ilomaki J
    J Diabetes; 2024 Apr; 16(4):e13507. PubMed ID: 38599885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
    Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dementia Diagnosis Is Associated with Changes in Antidiabetic Drug Prescription: An Open-Cohort Study of ∼130,000 Swedish Subjects over 14 Years.
    Secnik J; Xu H; Schwertner E; Hammar N; Alvarsson M; Winblad B; Eriksdotter M; Garcia-Ptacek S; Religa D
    J Alzheimers Dis; 2020; 76(4):1581-1594. PubMed ID: 32741836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes.
    Zhuo M; D'Andrea E; Paik JM; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Patorno E
    JAMA Netw Open; 2022 Oct; 5(10):e2235995. PubMed ID: 36219443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes.
    Foresta A; Ojeda-Fernandez L; Macaluso G; Roncaglioni MC; Tettamanti M; Fortino I; Leoni O; Genovese S; Baviera M
    Clin Ther; 2023 Apr; 45(4):e115-e126. PubMed ID: 36933975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose co-transporter-2 inhibitors and the risk of venous thromboembolism: A nationwide population-based study and meta-analysis.
    Tsai HR; Lin YJ; Yeh JI; Huang YC; Liu PP; Peng CC; Hsu JY; Lee YC; Loh CH; Lin SM; Huang HK
    Diabetes Metab Res Rev; 2024 Feb; 40(2):e3739. PubMed ID: 37862117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes.
    Zhuo M; Hawley CE; Paik JM; Bessette LG; Wexler DJ; Kim DH; Tong AY; Kim SC; Patorno E
    JAMA Netw Open; 2021 Oct; 4(10):e2130762. PubMed ID: 34705014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study.
    Vlacho B; Mata-Cases M; Mundet-Tudurí X; Vallès-Callol JA; Real J; Farre M; Cos X; Khunti K; Mauricio D; Franch-Nadal J
    Front Endocrinol (Lausanne); 2021; 12():708372. PubMed ID: 34335477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.
    Paul SK; Bhatt DL; Montvida O
    Eur Heart J; 2021 May; 42(18):1728-1738. PubMed ID: 33289789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.